A phase II trial using a universal GM-CSF [granulocyte-macrophage colony-stimulating factor]-producing and CD40L-expressing bystander cell line (GM. CD40L) in the formulation of autologous tumor cell-based vaccines for patients with mantle cell lymphoma

Trial Profile

A phase II trial using a universal GM-CSF [granulocyte-macrophage colony-stimulating factor]-producing and CD40L-expressing bystander cell line (GM. CD40L) in the formulation of autologous tumor cell-based vaccines for patients with mantle cell lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs CD40L GVAX (Primary) ; Aldesleukin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Prednisone; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Oct 2017.
    • 06 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
    • 31 Jan 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top